BIOMIMESYS® has taken place in the panel of the future medicine on the 27th of September. The next step has arrived, and Nathalie Maubon CEO of HCS Pharma has taken BIOMIMESYS® all the way to Asia. Our innovative and reliable 3D cell culture system is adapted to high throughput formats Read more…
We are really pleased to announce that we will be present in BioAsia-Taiwan and present our breakthrough technology BIOMIMESYS alongside our partners Molecular Devices (USA) and LumiSTAR Biotechnology (TW). We are 3 companies in 3 different continents unifying their strenghs to develop the best strategy to find new and more Read more…
BIOMIMESYS® is a patented 3D matrix reproducing the physicochemical properties of the extracellular matrix (ECM), different from classical hydrogels used for 3D cell culture. It is composed of native ECM components: Hyaluronic Acid (HA) combined with collagens, adhesion peptides… in the form of a unique hydroscaffold, i.e. exhibiting a dual Read more…
Industry and academia are increasingly complexifying their in vitro models, not only 3D models but also organs-on-chip (OoC) in their studies. Such systems are needed for putting different tissues into contact, or to take into account flux-related aspects. BIOMIMESYS® being an ideal hydroscaffold™ for 3D cell culture, this webinar aims Read more…
About 90% of drug candidates fail in clinical trials, for efficacy- and toxicity-related reasons, which often involve the Central Nervous System (CNS). This high failure rate highlights a lack of relevance in experimental models used upstream, including human in vitro models. Indeed, they do not take into account the complexity Read more…
Presentation in english Environ 90 % des candidats médicaments échouent aux essais cliniques, notamment en neurologie, faute d’efficacité. Cela met en évidence un manque de pertinence dans les modèles précliniques, y compris les modèles in vitro, qui ne prennent pas en compte le microenvironnement, composé par les cellules gliales et Read more…
Présentation en français About 90% of drug-candidates failed in clinical trials, in particular in neurology, due to a lack of efficacy. That highlights a lack of relevance in preclinical models, including in vitro models, which do not take into account the microenvironment, composed by glial cells and the Extracellular Matrix Read more…
Solid tumors are associated with a modified microenvironment, in particular an enhanced collagen content and increased stiffness at the level of the extracellular matrix (ECM). These ECM changes are now recognized as important drivers of cancer initiation, progression, and propagation, and also impact the responses of cancerous cells to treatments. Read more…
3D cell culture systems have recently emerged as promising tools for reproducing the cellular environment and the organization of tissues/organs, where cells are connected to each other and to the surrounding extracellular matrix (ECM). In this webinar we will focus on BIOMIMESYS® Liver and will discuss about its different applications. Read more…
3D cell culture systems have recently emerged as promising tools for reproducing the cellular environment and the organization of tissues/organs, where cells are connected to each other and to the surrounding extracellular matrix (ECM). BIOMIMESYS® hydroscaffold technology based on crosslinking Hyaluronic Acid (HA) and extracellular matrix compounds reproduces tissue microenvironment Read more…
HCS Pharma était présent au Workshop OoC pour une création et une structuration de la filière, organisé par Biovalley à l’Institut Pierre-Gilles de Gennes (Paris). Nous sommes très heureux d’avoir pu sponsoriser l’événement, mais aussi tout simplement d’y avoir participé – en présentiel – et de pouvoir discuter avec des chercheurs Read more…
Solid tumors are associated with a modified microenvironment, in particular an enhanced collagen content and increased stiffness at the level of the extracellular matrix (ECM). These ECM changes are now recognized as important drivers of cancer initiation and progression, and also impact the responses of cancerous cells to treatments. Made Read more…
Our project leader Dr Meryl Roudaut was invited to present at the last ISVHLD congress, the Global Hepatitis Summit, in Taiwan. The theme of the summit, “Evolution and Revolution of Viral Hepatitis and Liver Disease”, was perfect to talk about the use of BIOMIMESYS® product to overcome the limitations of Read more…
Have you missed our last webinar with Molecular Devices about 3D oncology models? In April, our project leader Elodie was talking about how to establish and image physiologically relevant 3D cancer in vitro models, using BIOMIMESYS Oncology as a surrogate for the tumoral extracellular matrix. Our product BIOMIMESYS® Oncology matrix Read more…
Pharmaceutical industry is facing a very high failure rate in drug discovery, with 90% of failure in clinical trials. This is particularly true for central nervous system applications, with a rate of 30% safety failure in clinical trials, compared to 7% in preclinical trials (Cook et al. 2014). This reveals Read more…
3D cell culture systems have recently emerged as promising tools for reproducing the cellular environment and the organization of tissues/organs, where cells are connected to each other and to the surrounding extracellular matrix (ECM). In this webinar we will focus on BIOMIMESYS® Adipose Tissue and on the ongoing development of Read more…
3D cell culture systems have recently emerged as promising tools for reproducing the cellular environment and the organization of tissues/organs, where cells are connected to each other and to the surrounding extracellular matrix (ECM). In this presentation we will focus on BIOMIMESYS® Liver and will discuss about its different applications. Read more…
3D cell culture systems have recently as promising tools for reproducing the cellular environment and the organization of tissues/organs, where cells are connected to each other and to the surrounding extracellular matrix (ECM). Join us for this webinar to know more about BIOMIMESYS® technology, our 3D cell culture system designed Read more…
Just before Covid-19 pandemic crisis widely spread to France, we attended the User Meeting organized by Molecular Devices in Hilton Garden Inn Leiden (Oegstgeest, Netherlands). We enjoyed the programme, gathering a variety of topics but with high content analysis/screening as a common technique to answer diverse scientific questions. On the Read more…
It was a real pleasure for us to be invited at the last West Data Festival, to present our last developments in Artificial Intelligence dedicated to picture analysis. We warmly thank the organizers, Laval Mayenne Technopole and ATLANPOLE biotérapies for this opportunity. We also thank Laval Virtual to help us Read more…
Biomimesys is providing a great opportunity to culture human induced pluripotent stem cells (hiPSCs) in 3D and differentiate them into different kind of cell types including liver cells. Showcased by Méryl Roudaut at the 20th International Congress on In Vitro Toxicology (ESTIV2018), our co-development with the institute du thorax (U1087) Read more…
We are very happy to share with you about HCS and 3D in vitro models thanks to a labroots.com webinar on October 27, 2019! This webinar is made with our partner Molecular Devices and it will present you many tips on how to handle 3D cell culture systems such as Read more…
